- Home
- GMAB vs LNT Comparison
GMAB vs LNT Comparison
Compare GMAB & LNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- LNT
- Stock Information
- Founded
- GMAB 1999
- LNT 1917
- Country
- GMAB Denmark
- LNT United States
- Employees
- GMAB N/A
- LNT N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- LNT Power Generation
- Sector
- GMAB Health Care
- LNT Utilities
- Exchange
- GMAB Nasdaq
- LNT Nasdaq
- Market Cap
- GMAB 17.4B
- LNT 17.7B
- IPO Year
- GMAB N/A
- LNT N/A
- Fundamental
- Price
- GMAB $28.66
- LNT $67.34
- Analyst Decision
- GMAB Strong Buy
- LNT Buy
- Analyst Count
- GMAB 7
- LNT 8
- Target Price
- GMAB $41.50
- LNT $69.38
- AVG Volume (30 Days)
- GMAB 2.6M
- LNT 2.4M
- Earning Date
- GMAB 11-06-2025
- LNT 11-06-2025
- Dividend Yield
- GMAB N/A
- LNT 3.01%
- EPS Growth
- GMAB 132.41
- LNT 23.58
- EPS
- GMAB 25.10
- LNT 3.18
- Revenue
- GMAB $3,845,670,022.00
- LNT $4,274,000,000.00
- Revenue This Year
- GMAB $24.92
- LNT $7.01
- Revenue Next Year
- GMAB $15.97
- LNT $4.91
- P/E Ratio
- GMAB $11.14
- LNT $21.17
- Revenue Growth
- GMAB 29.57
- LNT 7.77
- 52 Week Low
- GMAB $17.24
- LNT $56.08
- 52 Week High
- GMAB $33.65
- LNT $69.75
- Technical
- Relative Strength Index (RSI)
- GMAB 40.06
- LNT 49.02
- Support Level
- GMAB $28.08
- LNT $65.93
- Resistance Level
- GMAB $29.35
- LNT $68.49
- Average True Range (ATR)
- GMAB 0.65
- LNT 0.95
- MACD
- GMAB -0.27
- LNT -0.24
- Stochastic Oscillator
- GMAB 25.93
- LNT 35.90
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About LNT Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light. Together, IPL and WPL serve nearly 1 million electric customers and 425,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.